Zacks Research Issues Positive Outlook for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Analysts at Zacks Research lifted their Q3 2025 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a report issued on Tuesday, January 7th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn $1.12 per share for the quarter, up from their previous estimate of $1.11. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q1 2026 earnings at $1.41 EPS.

HALO has been the subject of several other reports. JMP Securities upped their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $58.00 to $62.00 in a research note on Monday, October 7th. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price objective for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Piper Sandler raised their target price on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research report on Monday, November 4th. Finally, Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.11.

Halozyme Therapeutics Trading Up 5.0 %

HALO opened at $53.76 on Friday. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The stock has a market capitalization of $6.84 billion, a price-to-earnings ratio of 17.80, a P/E/G ratio of 0.44 and a beta of 1.24. The company has a 50-day simple moving average of $50.16 and a 200 day simple moving average of $54.00. Halozyme Therapeutics has a twelve month low of $33.15 and a twelve month high of $65.53.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Verdence Capital Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 1.9% in the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock valued at $757,000 after acquiring an additional 252 shares in the last quarter. GAMMA Investing LLC lifted its position in Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 350 shares during the last quarter. Private Advisor Group LLC lifted its position in Halozyme Therapeutics by 1.8% during the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company’s stock valued at $1,191,000 after purchasing an additional 412 shares during the last quarter. Juncture Wealth Strategies LLC grew its stake in Halozyme Therapeutics by 3.6% in the 3rd quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company’s stock worth $690,000 after buying an additional 415 shares in the last quarter. Finally, Diversify Advisory Services LLC lifted its stake in Halozyme Therapeutics by 8.5% during the third quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 418 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now owns 43,611 shares of the company’s stock, valued at $2,180,986.11. The trade was a 18.65 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.